-
Clinical Trials & Development5 days agoSonesitatug Vedotin Reduced the Risk of Death by 42% in 2nd- and Later-Line CLDN18.2-Positive Advanced Gastric/GEJ Cancers in CLARITY-Gastric01
25 October 2026 -- Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful...
-
Clinical Trials & Development5 days agoAntibody-Drug Conjugate Cuts Death Risk by 54% in Relapsed Small-Cell Lung Cancer
The phase III TAISHAN-302 trial found that the anti-B7-H3 antibody-drug conjugate Tam-Peli reduced the risk of death by 54 percent compared with topotecan in patients with...
-
Clinical Trials & Development5 days ago
Pfizer’s 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
NEW YORK--(BUSINESS WIRE) October 24, 2026 -- Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational...
-
Clinical Trials & Development5 days ago
Lilly Presents First Clinical Data in Platinum-Sensitive Ovarian Cancer for its Investigational, Next-Generation, FRα-targeting ADC Sofetabart Mipitecan
INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα)...
-
Clinical Trials & Development6 days agoESMO26: Lily’s sofe-m ADC stakes a claim in ovarian cancer
Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
-
Clinical Trials & Development6 days agoESMO26: Lilly’s sofe-m ADC stakes a claim in ovarian cancer
Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
-
Clinical Trials & Development6 days agoESMO26: BMS dual-acting ADC beats chemo in breast cancer
BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.
-
Clinical Trials & Development6 days ago
Novartis Remibrutinib Delivered Comprehensive Disease Control in Phase III RMS Trials, with Proven, Robust Safety Profile
Basel, October 23, 2026 – Novartis today presented positive results from the pivotal Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis (RMS) showing that...
-
Clinical Trials & Development6 days ago
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
OSAKA, Japan and CAMBRIDGE, Massachusetts, October 23, 2026 – Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent...
-
Clinical Trials & Development6 days ago
Precision T-Cell Therapy Invikafusp Alfa (Invika) Stalls Treatment-Resistant Cancers in Clinical Trial
October 23, 2026 -- Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the pioneering treatment may...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
